Paliperidone palmitate log-acting injection in patients with psychotic active clinic: start, change or increase of dose

Autor:	M.R. Raposo Hernandez, P. Manzur Rojas, A.L. Gonzalez Galdamez, A. Busaileh Salas, A. Gil Sánchez, C.J. Garcia Briñol, A. Belmar Simo, R. Sánchez Marín, I. Martínez Pérez, M.D. Piqueras Acevedo, F. González Jiménez, A. Rodriguez Hernandez, S. Gómez Bravo
Rok vydání:	2016
Předmět:	Paliperidone Palmitate medicine.medical_specialty Exacerbation business.industry medicine.medical_treatment Disease Antipsychotic treatment medicine.disease Psychiatry and Mental health Schizophrenia Internal medicine Medicine Quetiapine In patient business Antipsychotic Psychiatry medicine.drug
Zdroj:	European Psychiatry. 33:s249-s250
ISSN:	1778-3585 0924-9338
Popis:	The aim is to describe the experience of treatment with Paliperidone Palmitate long acting injection (PP) in patients with psychotic active clinic, whether diagnoses with schizophrenia or in patients with the first episode psychosis, as well as to reflect the improvement in the control of the symptoms that the patients can improve increasing the dose.MethodsWe have done a descriptive study of 34 patients hospitalized in psychiatry between January and July 2015 for psychotic active clinic who started treatment with PP or the previous dose was increased.Results91.2% of patients admitted for acute exacerbation of their usual pathology and 8.8% for a first episode psychosis. In the CGI scale, all the patients admitted scored as severe or markedly ill; going mostly mildly ill at discharge. For 55.9% of patients, the treatment was changed to PP, 29.4% of the dose was increased PP and 14.7% antipsychotic treatment was started with PP. Among patients change treatment, the main reason was non-adherence (47.4%). 70.6% of our patients were discharged with PP as only antipsychotic and 29.4% which was discharged with another antipsychotic, the most frequent association was of PP with Quetiapine (80%).ConclusionsPP is a highly effective medicament in the treatment of the schizophrenia that improves the adherence to the treatment, so in our experience and we consider it a medicament to be considered in the early stages of the disease. According to our experience and there are patients who can benefit from better control of symptoms adjusting the dose individually.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fafb0cad9b5fc50d9df6bc3aec8fbee3 https://doi.org/10.1016/j.eurpsy.2016.01.634 Zobrazit plný text záznamu